Related Experiment Videos
E-cadherin and beta-catenin are down-regulated in prostatic bone metastases
A A G Bryden1, J A Hoyland, A J Freemont
1Christie and Hope Hospital, University of Manchester, UK.
BJU International
|March 2, 2002
Summary
Down-regulation of E-cadherin and beta-catenin is observed in prostate cancer bone metastases, suggesting a role in metastasis development. This change is not consistently reflected in primary tumors.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- E-cadherin and beta-catenin are crucial cell adhesion molecules.
- Altered expression of these proteins is implicated in various cancers.
Purpose of the Study:
- To investigate the expression patterns of E-cadherin and beta-catenin in primary prostate cancer and bone metastases.
- To correlate expression levels with the metastatic phenotype.
Main Methods:
- Analysis of paired primary prostate cancer and bone metastasis specimens from 14 untreated patients.
- In-situ hybridization used to detect E-cadherin and beta-catenin mRNA expression.
- Expression levels graded as uniform, heterogeneous, or negative.
Main Results:
- E-cadherin mRNA detected in 13/14 primary tumors and 11/14 bone metastases.
- Beta-catenin mRNA detected in 13/13 primary tumors and 9/14 bone metastases.
- All metastases showed down-regulated E-cadherin and/or beta-catenin compared to primary tumors, with 9/13 primary tumors showing uniform expression.
Conclusions:
- Down-regulation of E-cadherin and beta-catenin is a characteristic of the metastatic phenotype in prostate cancer.
- These molecular changes may significantly contribute to the formation of bone metastases.
- The expression changes in metastases are not consistently mirrored in the primary tumors.